Clinical Trial Update: A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the effects and safety of Riliprubart for chronic inflammatory demyelinating polyneuropathy that does not respond to usual tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Riliprubart

Snippet

Sponsor: Sanofi | Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic | Phase 3 | Status: RECRUITING